Hospital Management Protocol for Pregnant Patients
All pregnant patients admitted to hospital require immediate multidisciplinary assessment involving obstetrics, with specific protocols varying by presenting condition, but certain universal principles apply across all admissions including VTE prophylaxis, blood pressure monitoring, and condition-specific management pathways.
Universal Assessment and Monitoring
Initial Evaluation
Upon admission, all pregnant patients require:
- Blood pressure measurement at every clinical encounter, with treatment initiated if BP ≥140/90 mmHg in clinic (or ≥135/85 mmHg if home monitoring) 1
- VTE risk stratification with weight-adjusted LMWH prophylaxis for all hospitalized pregnant women unless contraindicated (platelet count >30 × 10⁹/L, no active bleeding, delivery not anticipated within 24 hours) 2
- Proteinuria screening using automated dipstick urinalysis; if positive, quantify with urine protein/creatinine ratio (≥30 mg/mmol is abnormal) 1
- Complete blood count including hemoglobin, platelet count
- Liver and renal function tests including uric acid 1
Obstetric Consultation Requirements
Immediate obstetric consultation is mandatory for:
- Active or complicated inflammatory bowel disease 3
- Any hypertensive disorder requiring hospitalization 1
- Severe COVID-19 infection 2
- Major trauma 4
- Any condition requiring ICU-level care 5
Transfer to tertiary center with high-risk obstetrics program is required when:
- Pregnant women require hospitalization for IBD management 3
- Severe hypertensive disorders develop 1
- Critical illness necessitating intensive care 5
Condition-Specific Management Pathways
Hypertensive Disorders
Severe Hypertension (>160/110 mmHg):
- Requires urgent treatment in monitored setting 1
- First-line agents: oral nifedipine OR intravenous labetalol OR intravenous hydralazine
- If unavailable, use oral labetalol 1
- Target diastolic BP: 85 mmHg (systolic 110-140 mmHg) 1
- Reduce/cease antihypertensives if diastolic BP <80 mmHg 1
Preeclampsia Management:
- Initial hospital assessment mandatory at diagnosis 1
- Outpatient management possible only after establishing stability and reliable patient monitoring 1
- Magnesium sulfate prophylaxis indicated for: proteinuria with severe hypertension OR hypertension with neurological signs/symptoms 1
- Monitoring frequency: BP checks, twice-weekly blood tests (hemoglobin, platelets, liver/renal function, uric acid), clinical assessment including clonus 1
Delivery Indications at ≥37 weeks OR if:
- Repeated severe hypertension despite 3 antihypertensive classes
- Progressive thrombocytopenia
- Progressively abnormal liver/renal tests
- Pulmonary edema
- Severe intractable headache, visual scotomata, or convulsions
- Nonreassuring fetal status 1
Venous Thromboembolism
Treatment Protocol:
- LMWH is strongly preferred over UFH for acute VTE treatment 6
- Either once-daily or twice-daily LMWH dosing acceptable 6
- Routine anti-FXa monitoring NOT recommended 6
- Low-risk acute VTE: outpatient management acceptable 6
Prophylaxis During Admission:
- Weight-adjusted LMWH for all admitted pregnant women with COVID-19 (platelet count >30 × 10⁹/L, no active bleeding) 2
- Prolonged PT/APTT NOT a contraindication to thromboprophylaxis 2
- If anticoagulation contraindicated: mechanical prophylaxis (intermittent pneumatic compression) 2
Discharge Planning:
- Short hospitalization without delivery: 10-14 days LMWH 2
- Severe disease, high D-dimer, third trimester: continue LMWH throughout pregnancy and postpartum 2
- Postpartum: 2-6 weeks thromboprophylaxis depending on risk factors 2
COVID-19 Specific Considerations
Coagulopathy Monitoring:
- Use pregnancy-modified ISTH DIC score (96% specificity, 78% sensitivity) 2
- Elevated fibrin-degradation products are early pathological signs 2
- D-dimer levels guide duration of post-discharge anticoagulation 2
Home Management (Mild-Moderate Disease):
- VTE risk assessment mandatory
- Low risk: encourage hydration, nutrition, mobilization, pyrexia control
- LMWH prophylaxis if: immobility, high fever, dehydration, or additional VTE risk factors 2
Inflammatory Bowel Disease
Medication Continuation:
- Continue 5-ASA therapy (oral and/or rectal) throughout pregnancy 3
- Continue thiopurine therapy throughout pregnancy 3
- Continue anti-TNF therapy throughout pregnancy 3
- For low-risk patients with compelling reason to stop anti-TNF: last dose at 22-24 weeks gestation 3
Flare Management:
- Mild-moderate UC flare: optimize combination oral and rectal 5-ASA 3
- Disease flare on optimal maintenance: systemic corticosteroids or anti-TNF therapy 3
- Perianal sepsis in CD: metronidazole and/or ciprofloxacin 3
Immune Thrombocytopenia
Treatment During Pregnancy:
- First-line: corticosteroids or IVIG 7
- IVIG with corticosteroids when rapid platelet increase required 7
- IVIG dose: 1 g/kg as single dose, repeat if necessary 7
Delivery Management:
- Mode of delivery based on obstetric indications (not platelet count) 7
Critical Care Considerations
ICU Admission Criteria:
- Consultant-level multidisciplinary input mandatory 5
- Maternal stabilization and timely diagnosis take priority 5
- Pregnant women must not be disadvantaged in access to life-saving interventions 5
- Attention to psychological well-being and lactation support essential 5
Common Pitfalls to Avoid
- Do not delay VTE prophylaxis due to prolonged PT/APTT—these are not contraindications 2
- Do not use dextrose solutions for IV fluid management in hyperemesis/preeclampsia—use 0.9% normal saline to prevent Wernicke's encephalopathy 1
- Do not withhold imaging or contrast when maternal diagnosis is critical—maternal stabilization takes priority 5
- Do not stop IBD maintenance therapy during pregnancy—disease activity poses greater risk than medications 3
- Do not use intravenous hydralazine as first-line for severe hypertension—excess perinatal adverse effects 8
Documentation Requirements
All units managing pregnant patients should: